Loyal Highlights Progress on LOY-002 and Plans Series C Use for Regulatory and Commercial Push

According to a recent LinkedIn post from Loyal, Founder & CEO Celine Halioua highlights the company’s long-term focus on developing what it aims to be the first FDA-approved drug for lifespan extension, targeting senior dogs. The post points to LOY-002 as the lead drug candidate and indicates that a recently raised Series C round is intended to fund final regulatory work and commercialization efforts.

The post suggests Loyal is progressing toward late-stage regulatory milestones, which may signal a transition from primarily R&D-focused operations toward potential revenue generation if approvals are obtained. For investors, successful approval and commercialization of LOY-002 could position Loyal as an early mover in the companion-animal longevity market, though execution risk around FDA review, market adoption, and pricing remains a key variable for the company’s financial outlook.